Trials / Completed
CompletedNCT04914429
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 327 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Guselkumab 100 mg will be administered as a SC injection. |
| DRUG | Placebo | Matching placebo will be administered as a SC injection. |
Timeline
- Start date
- 2021-08-25
- Primary completion
- 2023-09-26
- Completion
- 2023-09-26
- First posted
- 2021-06-04
- Last updated
- 2023-10-12
Locations
26 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04914429. Inclusion in this directory is not an endorsement.